Collegium Pharmaceutical, Inc (COLL)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
- Symbol
- COLL
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $729.59M
- 52 week range
- 21.65 - 50.79
Valuation
- Share price
- $22.45 (close of 2026-09-23)
- P/E (TTM)
- 14.67x
- Price to book
- 2.34x
- Price to free cash flow
- 2.22x
- Enterprise value
- $1.70B
- Book value per share
- $9.60
Price performance
| Period | Change |
|---|
| 1 day | -2.56% |
| 5 days | +2.79% |
| 1 month | -17.19% |
| 3 months | -35.15% |
| 6 months | -35.38% |
| Year to date | -51.51% |
| 1 year | -35.67% |
| 3 years | +0.86% |
| 5 years | +10.10% |
| 10 years | +45.02% |
| All time | +82.67% |
Profitability and growth
- Return on equity
- 20.84%
- Return on invested capital
- 16.93%
- Return on assets
- 3.79%
- Return on capital employed
- 14.76%
- Gross margin
- 59.35%
- Net margin
- 8.05%
- EBITDA margin
- 23.55%
- Revenue growth
- 23.62%
- Net income growth
- -9.13%
- Free cash flow growth
- 61.11%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 45.00%
- Current ratio
- 1.03x
- Net debt to EBITDA
- 2.49x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $780.57M
- Cost of revenue
- $317.31M
- Gross profit
- $463.26M
- EBITDA
- $183.82M
- Net income
- $62.87M
- Earnings per share
- $1.98
- Shares outstanding
- 31.71M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $780.57M | $463.26M | $62.87M | $1.98 |
| 2024-12-31 | $631.45M | $377.34M | $69.19M | $2.14 |
| 2023-12-31 | $566.77M | $326.17M | $48.16M | $1.43 |
| 2022-12-31 | $463.93M | $209.49M | $-25.00M | $-0.74 |
| 2021-12-31 | $276.87M | $150.62M | $71.52M | $2.05 |
| 2020-12-31 | $310.02M | $179.84M | $26.75M | $0.78 |
| 2019-12-31 | $296.70M | $103.04M | $-22.72M | $-0.68 |
| 2018-12-31 | $280.41M | $114.74M | $-39.13M | $-1.19 |
| 2017-12-31 | $28.48M | $25.88M | $-74.86M | $-2.47 |
| 2016-12-31 | $1.71M | $1.50M | $-94.18M | $-3.88 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 59.35% | 8.05% | 20.84% | 16.93% |
| 2024-12-31 | 59.76% | 10.96% | 30.23% | 13.81% |
| 2023-12-31 | 57.55% | 8.50% | 24.64% | 22.10% |
| 2022-12-31 | 45.15% | -5.39% | -12.83% | 4.56% |
| 2021-12-31 | 54.40% | 25.83% | 35.24% | 69.77% |
| 2020-12-31 | 58.01% | 8.63% | 14.38% | 258.77% |
| 2019-12-31 | 34.73% | -7.66% | -25.99% | - |
| 2018-12-31 | 40.92% | -13.95% | -42.72% | - |
| 2017-12-31 | 90.89% | -262.91% | -71.93% | - |
| 2016-12-31 | 87.55% | -5504.15% | -69.81% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $231.25M | - |
| 2024-12-31 | $70.56M | - |
| 2023-12-31 | $238.95M | - |
| 2022-12-31 | $173.69M | - |
| 2021-12-31 | $186.43M | - |
| 2020-12-31 | $174.12M | - |
| 2019-12-31 | $170.02M | $11.50M |
| 2018-12-31 | $146.63M | $11.50M |
| 2017-12-31 | $118.70M | - |
| 2016-12-31 | $153.22M | $4.15M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $327.58M | $41.91M |
| 2024-12-31 | $203.33M | $32.40M |
| 2023-12-31 | $274.29M | $27.14M |
| 2022-12-31 | $122.61M | $22.87M |
| 2021-12-31 | $101.61M | $24.25M |
| 2020-12-31 | $88.40M | $21.91M |
| 2019-12-31 | $21.34M | $16.53M |
| 2018-12-31 | $163.91M | $13.78M |
| 2017-12-31 | $-68.01M | $7.95M |
| 2016-12-31 | $-75.53M | $5.79M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $1.58
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $1.48 |
| 2026-05-07 | - | - |
| 2026-02-26 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-27 | - | - |
| 2025-02-20 | - | - |
Filings and sources
- Company website
- collegiumpharma.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades